| |
Patient 14
|
Patient 15
|
Patient 16
|
Patient 17
|
Patient 18
|
Patient 19
|
Patient 20
|
Patient 21
|
|---|
|
DAS28
| | | | | | | | |
|
M0
|
4.02
|
4.52
|
5
|
4.58
|
5.41
|
6.2
|
5.23
|
4.92
|
|
M3 (absolute value)
|
2.82
|
3.85
|
4.3
|
2.88
|
3.18
|
1.1
|
5.1
|
4.70
|
|
M3 EULAR response (yes/no)
|
Yes (good)
|
No
|
Yes (moderate)
|
Yes (good)
|
Yes (good)
|
Yes (remission)
|
No
|
No
|
|
M6 (absolute value)
|
1.95
|
4.01
|
5.34
|
3.12
|
NA
|
NA
|
NA
|
NA
|
|
M6 EULAR response (yes/no)
|
Yes (remission)
|
No
|
No
|
Yes (good)
|
NA
|
NA
|
NA
|
NA
|
|
ASDAS
| | | | | | | | |
|
M0
|
2.41
|
4.03
|
MD
|
MD
|
MD
|
3.8
|
3
|
MD
|
|
M3 (absolute value)
|
1.50
|
2.64
|
MD
|
MD
|
MD
|
1.35
|
3.1
|
MD
|
|
M6 (absolute value)
|
1.03
|
2.79
|
MD
|
MD
|
MD
|
NA
|
NA
|
MD
|
|
SJCa
| | | | | | | | |
|
M0
|
7
|
2
|
2
|
0
|
3
|
9
|
4
|
7
|
|
M3 (absolute value)
|
NA
|
NA
|
NA
|
NA
|
7
|
0
|
3
|
6
|
|
M6 (absolute value)
|
0
|
6
|
1
|
0
|
NA
|
NA
|
NA
|
NA
|
|
TJCa
| | | | | | | | |
|
M0
|
7
|
6
|
5
|
5
|
0
|
15
|
7
|
12
|
|
M3 (absolute value)
|
NA
|
NA
|
NA
|
NA
|
0
|
0
|
6
|
11
|
|
M6 (absolute value)
|
2
|
4
|
3
|
8
|
NA
|
NA
|
NA
|
NA
|
|
BASDAI, 0 to 100
| | | | | | | | |
|
M0
|
42
|
75
|
NA
|
79.4
|
67
|
48
|
4.7
|
NA
|
|
M3 (change from M0; %)
|
-31
|
-6.7
|
NA
|
-9
|
+6
|
NA
|
-2.1
|
NA
|
|
M6 (change from M0; %)
|
-59.5
|
-4.7
|
NA
|
-32
|
NA
|
NA
|
NA
|
NA
|
|
BASFI, 0 to 100
| | | | | | | | |
|
M0
|
40
|
72
|
MD
|
MD
|
54
|
70
|
NA
|
NA
|
|
M3 (change from M0, %)
|
-17.5
|
-26
|
MD
|
MD
|
+44
|
NA
|
NA
|
NA
|
|
M6 (change from M0, %)
|
-12.5
|
-12.5
|
MD
|
MD
|
NA
|
NA
|
NA
|
NA
|
|
Pain VAS, 0 to 10
| | | | | | | | |
|
M0
|
1.5
|
7
|
5
|
7
|
7
|
5
|
6
|
8
|
|
M3 (absolute value)
|
2
|
8
|
NA
|
6
|
8
|
1
|
6.5
|
6
|
|
M6 (absolute value)
|
1
|
9
|
6
|
7.5
|
NA
|
NA
|
NA
|
NA
|
|
PGA, 0 to 10
| | | | | | | | |
|
M0
|
1
|
6
|
7
|
7.5
|
7
|
5.2
|
6.5
|
8
|
|
M3 (absolute value)
|
3.5
|
6
|
MD
|
MD
|
7
|
1
|
6.5
|
8
|
|
M6 (absolute value)
|
1.2
|
6
|
8
|
MD
|
NA
|
NA
|
NA
|
NA
|
|
CRP (mg/dl)a
| | | | | | | | |
|
M0
|
20.2
|
17
|
119
|
12
|
112.3
|
65
|
4
|
1
|
|
M3 (absolute value)
|
NA
|
NA
|
NA
|
NA
|
9.5
|
1
|
5
|
1
|
|
M6 (absolute value)
|
0.4
|
0.8
|
128
|
1
|
NA
|
NA
|
NA
|
NA
|
|
ESR (mm)a
| | | | | | | | |
|
M0
|
39
|
22
|
67
|
26
|
103
|
60
|
27
|
7
|
|
M3 (absolute value)
|
NA
|
NA
|
NA
|
NA
|
8
|
4
|
7
|
8
|
|
M6 (absolute value)
|
5
|
7
|
70
|
2
|
NA
|
NA
|
NA
|
NA
|
- ASDAS, Assessment of SpondyloArthritis International Society endorsed disease activity score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; CRP, C-reactive protein; DAS28, Disease Activity Score in 28 joints; ESR, erythrocyte sedimentation rate; EULAR, European League Against Rheumatism; M0, month 0 (baseline); M3, month 3; M6, month 6; NA, not available; MD, missing data; PGA, patient's global assessment of disease activity; SJC, swollen joint count; TJC, tender joint count; VAS, visual analogue scale. aFor SJC, TJC, CRP, and ESR, the table shows only the values at baseline (M0) and at last follow-up (M3 or M6).
